123 results
Antiplatelet Conversion - Switching Between P2Y12 Inhibitors
Oral P2Y12 inhibitors vary in potency and pharmacokinetic and dynamic
Antiplatelet Conversion ... Switching Between P2Y12 ... Inhibitors Oral P2Y12 ... Switching P2Y12 ... Inhibitor #switching #conversion
Loop diuretic PO --> IV conversions 

Furosemide 40 mg PO = Furosemide 20 mg IV =
diuretic PO --> IV conversions ... Equivalent #Dose #Conversion
Antiplatelet Medications - Summary Table

Aspirin - Inhibits cyclooxygenase, preventing formation of thromboxane A2
 • Acute coronary
combination with P2Y12 ... anticoagulation in a-fib P2Y12 ... - Inhibits the P2Y12
Common IV to PO Drug Conversions
1) Metoprolol 1:2.5
2) Diltiazem Oral Dose(mg/day) = [ rate (mg/hr) x
IV to PO Drug Conversions ... #IVtoPO #Drug #Conversion
Metoprolol and Carvedilol - Immediate to Extended Release Dose Conversions

Metoprolol 
Immediate (tartrate) -> Extended (succinate) 
25
Extended Release Dose Conversions ... ExtendedRelease #Dose #Conversion
Antiplatelet Conversion - P2Y12 Inhibitor Switching
 • Clopidogrel (Plavix)
 • Prasugrel (Effient)
 • Ticagrelor (Brilinta)
Clopidogrel and
Antiplatelet Conversion ... - P2Y12 Inhibitor ... active site of the P2Y12 ... #Antiplatelet #Conversion ... #P2Y12 #Inhibitor
Angiotensin Receptor Blockers 
Recommended Dose Conversions 

Valsartan 
Irbesartan 
Losartan 
Olmesartan 
Telmisartan 
Candesartan 
Azilsartan 
Eprosartan 

A few
Recommended Dose Conversions ... at-a-glance dose conversion ... Blockers #ARB #Conversion
Cangrelor - Pharmacology
Cangrelor (Kengreal) is a parenteral analogue of adenosine triphosphate
Cangrelor binds reversibly to the platelet
Pharmacology Cangrelor (Kengreal ... to the platelet P2Y12 ... pre-treated with an oral P2Y12 ... if the platelet P2Y12 ... stopped #Cangrelor #Kengreal
Transdermal Fentanyl require unique dosing conversions. For Adult and pediatric patients taking opiouds or doses not
unique dosing conversions ... Opiate #Opioid #Conversion
Antiplatelet Conversion - Switching Between Oral P2Y12 Inhibitors
A, Switching between oral agents in the acute/early phase.
Antiplatelet Conversion ... Switching Between Oral P2Y12 ... CIRCULATIONAHA.117.031164 #P2Y12 ... Inhibitor #switching #conversion